NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Endometrial Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, metastatic neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, stomach disorder, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-10-06 | NCT06586957 | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Advanced Liver Cancers | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT04524871 | |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-08-28 | NCT07029399 |